Regulatory perspective of early phase I/II designs, including basket, umbrella and platform designs
Presented by Khadija Rantell
Disclaimer

The views expressed in this presentation are those of the speaker and not necessarily those of the MHRA.
Abbreviations

B/R: Benefit/Risk
CHMP: Committee for Medicinal Products for Human Use
CTA: Clinical Trial Authorisation
CTFG: Clinical Trials Facilitating Group
DD: Drug Development
D-E-R: Does-Exposure-Response
ICH E9: Statistical Principles for Clinical Trials
ICH E4: Dose-Response Information to Support Drug Registration
ICH E8: General Considerations for Clinical Trials
EAG: Expert Advisory Group
EMA: European Medicine Agency
MAA: Marketing Authorisation Application
MSWP: Modelling and Simulation Working Party
NCA: National Competent Authority
PDCO: EU Paediatric Committee
PK: Pharmacokinetics
SA: Scientific Advice (National and European)
SAWP: Scientific Advice Working Party
Marketing Authorisation

European Directive 2001/83/EC  MHRA

• **Legislation** requires that marketing authorisation for a medicinal product shall be **refused** if:
  (a) the **risk-benefit** balance is not considered to be favourable; or
  (b) its **therapeutic efficacy** is insufficiently substantiated by the applicant; or
  (c) its qualitative and quantitative composition is not as declared.

• “**therapeutic efficacy**” is considered in terms of the clinical relevance as well as statistical significance.
Plan

There are two parts to this talk

• **Part I:** Early Phase I/II

• **Part II:** Novel study designs (adaptive designs, master protocols: basket, umbrella, platform, matrix designs)
Phase I trials - Key questions

Is the drug **safe** and at **which dose**?

**Which patient** population? and

**Which drug/regimen** to prioritise?
ICH E8 – Early Phase trials

- **Phase I** studies typically involve one or a combination of the following aspects:
  - a) *Estimation of Initial Safety and Tolerability*
  - b) *Pharmacokinetics*
  - c) *Assessment of Pharmacodynamics*
  - d) *Early Measurement of Drug Activity*

- **Phase II** studies seek to explore therapeutic efficacy and involves the following aspects:
  - a) *Determine the dose(s) and regimen for the Phase III*
  - b) *Evaluation of potential endpoints, therapeutic regimen, and target population*
Current recommendations under ICH E4

• **D-E-R** is an integral part of drug development.

• **PK** information can be used to choose a wide range of doses.

• Trials should be well-controlled using appropriate approaches to minimise bias e.g. randomisation and blinding.

• Pros and Cons of different study designs are discussed.

• Focus should be on the dose-response function, not individual pairwise comparisons.

• **No loss of time and minimal extra effort is needed compared to DD plans that ignore dose-response**
Motivation

• During regulatory assessment lack of information related to E-R will increase uncertainties, may delay approval, and create additional regulatory requirements in terms of post approval commitments.

• Doses are rarely formally optimised in Phase II studies, selecting the right dose based on robust Phase I and II dose-finding studies is paramount.

• Good dose finding and D-E-R can:
  • serve as evidence of efficacy (unmet medical need)
  • support a single pivotal study
  • provide a strong database to support extrapolation to other groups e.g. paediatrics
  • be used to address limitations of data and uncertainties at the stage of MAA

Regulatory expectations

• **DR** relationship should examined in all stages of the **DD**.

• **ER** analysis is the method of choice for finding the proper dosing regimen for new medicine and for optimising the dosing regimen in new populations and indications.

• The dose finding strategy should be tailored to the specific development needs.

• **All methods are acceptable if fit for purpose.**

• **Regulators are open to new innovative methods for drug development. Early dialogue with regulators is recommended.**
Qualification of novel methodologies (2009)

- This is a voluntary scientific pathway to facilitate communication between the scientific community and regulators and to address challenges in DD. The qualification process lead to either:

  (i) CHMP Qualification Opinion on the acceptability of a specific use of the proposed method, based on the assessment of submitted data (public, e.g. MCP-Mod)

  (ii) CHMP Qualification Advice on future protocols and methods for further method development towards qualification, based on the evaluation of the scientific rationale and on preliminary data submitted (confidential).

- Guidance to applicant documents available at EMA website.
MSWG (2013)

• The **MSWG** was established in January 2013 to provide specialist scientific support to the **SAWP, PDCO** and **CHMP**.

• The **MSWG** responsibilities include assessment of modeling methodology.

• The **MHRA** are members of the **MSWG**.

• Examples of use of modelling and simulation include:
  • Paediatric Dose Finding/Extrapolation
  • Dose Selection
  • Inform SmPC (label)

• Publications on MS are available at the EMA website
EMA report from dose-finding workshop (2014)

- **Misperception** that exploratory development and dose finding is the company’s risk.
- For **B/R evaluation**, dose-selection should be based on the totality of data

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529745/pdf/PSP4-6-418.pdf
EMA report from dose-finding workshop (2014)

Different methods for data analysis/and or study designs are summarised

- Information from preclinical and phase I studies
  - FIM based methods
  - PK/PD Modelling and Simulations
  - Adaptive methods

- Phase 2 study design optimization
  - Regression models
  - PK/PD Modelling and Simulations
  - Quantitative systems pharmacology
  - MCP-mod/model averaging

- Characterisation of DER

- Dose selection for Phase 3 studies

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529745/pdf/PSP4-6-418.pdf
MHRA experience: based on assessment + SA

• **Phase I** designs have become complicated and yet algorithm based designs (e.g. A+B designs) are still the design of choice.

• Sponsors lack expertise on *model-based* methods and are not involving the external expert.

• Complex designs but without link to simple decision making rules.

• Weak early phase trials with limited data on **D-E-R** characterisation.

• Continued use of sub-optimal method e.g. pairwise comparison for dose(s) selection.
Part II: Innovative trial designs
Our goal

“As the UK seeks to do more complex and innovative trials, MHRA needs to continue engaging with sponsors to assist with innovative protocol designs and should facilitate efficient approval of complex trials and amendments to such trials, for example, to add new arms.

The UK should attempt to lead the innovation in clinical trial methodology, such as basket trials, and should also attempt to embed routine genomic analysis to make trials more targeted, smaller and more likely to deliver high efficacy.”

Master protocols are new approaches to clinical trials driven by the need for enhanced efficiency (patients and resources).
Clinical trials– standard vs complex designs

➢ A clinical trial is a clinical investigation with a **pre-defined objective** aimed at addressing **a precise hypothesis**.

➢ A complex clinical trial (investigating several IMPs/ and or populations) submitted as one trial is expected to have an ‘**overarching hypothesis**’ defining the scientific objective(s) of the **whole trial**.

➢ **Prospective planning** of adaptations is crucial to avoid biases.

➢ The **B/R** balance should be positive both for the entire trial and for each sub-protocol.
What will be covered

- How MHRA support innovative designs
- Current regulatory approaches
- Challenges
- Top tips!
Supporting innovative designs

• In the UK, the Experimental Cancer Medicine Centre (ECMC) Network is at the forefront of developing and delivering innovative trials.

• The MHRA welcomes and supports safe innovative approaches to clinical trials.

• The MHRA has also a representative at the Clinical Trial Facilitation Group (CTFG) of the Heads of Medicinal Agencies (HMA) whose responsibilities included promoting harmonisation of clinical trials assessment decisions and the administrative process across the NCA (e.g. MHRA).

• The MHRA provide input to the MRC/NIHR funding group by highlighting gaps in clinical trials methodologies as identified by the regulators.

• At the European level, a policy position paper on umbrella and basket trials has been drafted by the Biostatistics Working Party (BSWP).

• The CTFG has published a paper which represents European view regarding authorisation and conduct of clinical trials with complex trial designs.

Innovative trials designs

• The first hurdle in innovative trials is lack of common terminology.

• Assessment should be based on trial design elements rather than terminology used to describe the study.

• Adaptations can be acceptable if safe and scientifically justified.

• Future adaptations must be pre-specified as much as possible.

• Standard statistical principles are also applicable to innovative trial designs e.g. implication of interim analyses on the overall integrity of the trial and Type I error control.
Innovative designs: Basket trials

Multiple types of cancer
1 common genetic mutation (○)

Test drug

Note: Use of a common control is not always suitable but may help to put the results into perspectives

Innovative designs: Umbrella trials

Note: Design may be randomised or use external controls depending on the disease.

Innovative designs: Platform

MORPHEUS: Novel CIT platform
Efficient & confident combo development

Multi-indication
- "One protocol per tumor"

Multi-basket
- "All-comers" and "Biomarker defined subgroup refinement"

Randomized
- "Signals always evaluated vs SOC to improve confidence"

Longitudinal
- "Reverse-translational science with mandatory biopsies prior to 2L treatment"

Adaptable
- "Add or remove combinations via planned amendments"

NSCLC
Pancreatic
Gastric
HR+ BC
TNBC
CRC
UBC

1L all-comers
2L all-comers
Biomarker

Combo 1
Combo 2
Combo 3
Combo 2
Combo 3

SOC control

Faster and more confident decisions
Potential for accelerated approval
Innovative designs: Seamless phase
MHRA experience

Master Protocols (MHRA, initial applications)

Number of Clinical trial applications

Year of application

- umbrella
- basket
- platform
- matrix

2015
2016
2017
2018
Common issues

- Adaptations can be acceptable if safe and scientifically justified.
- Allocation of single EudraCT number to a complex trial is challenging but acceptable if the trial is safe and scientifically sound.
- Approval is based on safety considerations, scientific rationale and whether the Sponsor is be able to justify:
  - the choice of a complex trial design and explain why it is superior to a simpler, traditional design.
  - that future adaptations are consistent with the original trial hypothesis and should be stated up front as much as possible.
  - the statistical considerations (stopping criteria, Type I error control, bias, data pooling,…) are in place.
  - the trial has a beginning and an end. Never ending trials may be acceptable but the judgment is made on case by case basis.
- Subjects should only be included in comparisons for which they would have been eligible at randomisation
Characteristics of innovative trials (MHRA CTA)

• 2-3/90 CTA per month have innovative designs.

• All trials with innovative designs were conducted in oncology patients (CHMP guideline anti-cancer treatment updated).

• All were Phase I/II studies.

• Majority of CTA are approved or pending approval.
Innovative designs statistical challenges

• Master protocols have raised a number of challenging regulatory and statistical questions, especially as regards the control of the **Type I error rate**.

• **Type I error control** is not an issue for regulators in early/exploratory phase trials. However, it should be born in mind to avoid taking forward too many ineffective treatments to later phases.
Innovative designs statistical challenges

• In a **confirmatory setting**, the following should be considered:
  – Independence of sub-studies (umbrella, basket, and platform)
  – Use of shared control (umbrella)
  – Randomisation to sub-studies (umbrella)
  – Overlapping populations (basket)
  – Pooling (basket)
  – Differences in subgroup analyses (basket)
  – Adding, removing treatment arms, adaptive designs (platform)
  – Structural changes to patients population (platform)

• Two relevant publications are expected from the BSWG (EMA) and ECMC, which will include statistical considerations of innovative designs and recommendation on complex trials, respectively.
Summary

➢ The MHRA are tracking and gaining more experience in innovative designs
➢ The biggest barrier from our perspective for any clinical trial related issue/concern is not coming to ask our advice early enough (or at all!).
➢ We can offer:
  • Scientific advice
    • [https://www.gov.uk/guidance/medicines-get-scientific-advice-from-mhra](https://www.gov.uk/guidance/medicines-get-scientific-advice-from-mhra)
  • Broader scope meetings
  • Regulatory advice
  • Innovation office meetings
    • [https://www.gov.uk/government/groups/mhra-innovation-office](https://www.gov.uk/government/groups/mhra-innovation-office)
    • innovationoffice@mhra.gov.uk
  • SCOPE meetings – is it a CTIMP or not?
  • Email advice – clintrialhelpline@mhra.gov.uk
  • Telephone assistance – 020 3080 6456
Thank you for your attention
Acknowledgment

Maria Beatrice Panico (MHRA)
Kirsty Wydenbach (MHRA)
David Brown (MHRA)
References

➢ Qualification of novel methodologies for drug development: guidance to applicants

➢ EMA Report from dose-finding workshop.

➢ Recommendation paper on the initiation and conduct of complex trials

➢ New clinical trial designs in the era of precision medicines: An overview of definitions, strengths and weaknesses, and current use in oncology

About copyright
All material created by the MHRA, including materials featured within these MHRA presentation notes and delegate pack, is subject to Crown copyright protection. We control the copyright to our work (which includes all information, database rights, logos and visual images), under a delegation of authority from the Controller of Her Majesty’s Stationery Office (HMSO).

The MHRA authorises you to make one free copy, by downloading to printer or to electronic, magnetic or optical storage media, of these presentations for the purposes of private research, study and reference. Any other copy or use of Crown copyright materials featured on this site, in any form or medium is subject to the prior approval of the MHRA.

Further information, including an application form for requests to reproduce our material can be found at www.mhra.gov.uk/crowncopyright

Material from other organisations
The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned.